The $100 Million IND
Executive Summary
An extraordinary series of high-value IND-stage deals could help to solve what has always been the intractable problem for biotechs: how to fund late-stage product development and simultaneously re-fill the early-stage pipeline. Still, it will be the rare biotech that can pull off this strategy--which requires INDs in the hottest areas of pharmaceutical development.
You may also be interested in...
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Though clinical proof-of-concept has long been the goal of fledgling biotechs hoping to land a deep-pocketed partner or acquirer, data suggest reaching this inflection point may no longer provide an optimal risk-reward balance. Biotechs would be wise to partner earlier.
IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Though clinical proof-of-concept has long been the goal of fledgling biotechs hoping to land a deep-pocketed partner or acquirer, data suggest reaching this inflection point may no longer provide an optimal risk-reward balance. Biotechs would be wise to partner earlier.
Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout
Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.